|
Age group (years)
|
Positive no./examined no. (%)
|
Assemblage (n)
|
Sub-assemblage (n)/accession no.
|
MLGs (n)
|
|---|
|
SSU rRNA
|
bg
|
tpi
|
gdh
|
|---|
|
Children (< 5)
|
0/26
| | | | | |
|
Minors (5–17)a
|
22/225 (9.78)
|
A (3)
|
AII (1)/OM001823
|
AII (1)/OM001842
|
AII (1)/OM001857
|
MLG-AII (1)
|
|
B (19)
| | |
B1 (1)/OM001858
| |
|
B1 (1)/OM001824
|
B1 (1)/OM001843
|
B2 (1)/OM001859
|
MLG-B1 (1)
|
|
Young adults (18–35)
|
0/31
| | | | | |
|
Middle-aged adults (36–60)a
|
1/83 (1.20)
|
A (1)
|
AII (1)/OM001823
| | | |
|
Older adults (> 60)
|
1/48 (2.08)
|
A (1)
| | | | |
|
Total
|
24/413 (5.81)
|
A (5), B (19)
|
AII (2), B1 (1)
|
AII (1), B1 (1)
|
AII (1), B1 (1), B2 (1)
| |
- One novel sequence obtained in the present study is highlighted in bold
- aA significant difference in prevalence is observed only between the age groups of 5–17 and 36–60 years
